A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
NCT ID: NCT03998514
Last Updated: 2021-05-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
88 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-07-09
Study Completion Date
2021-04-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending subcutaneous (SC) doses of CB4211 in healthy non obese subjects and subjects with NAFLD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases
NCT06891365
Healthy Volunteers
Hepatic Steatosis
RECRUITING
PHASE1
First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases
NCT05599945
Healthy Volunteers
Hepatic Steatosis
COMPLETED
PHASE1
6-week Safety and PD Study in Adults With NAFLD
NCT03256526
Non-alcoholic Fatty Liver Disease
COMPLETED
PHASE2
2-Week Study In People With Nonalcoholic Fatty Liver Disease
NCT03513588
Non-alcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
COMPLETED
PHASE1
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT05395481
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Part A: Part A is a randomized, double blind, placebo controlled, single ascending dose sequential group study evaluating the safety, tolerability, PK, and PD of a single SC dose of CB4211 in healthy non obese subjects.
Part B: Part B is a randomized, double blind, placebo controlled, multiple ascending dose sequential group study evaluating the safety, tolerability, PK, and PD of once daily SC doses of CB4211 over 7 days in healthy non obese subjects.
Part C: Part C is a randomized, double blind, placebo controlled, multiple dose, parallel group study evaluating the safety, tolerability, PK, and PD of once daily SC doses of CB4211 over 28 days in subjects with NAFLD.
Part B: Part B is a randomized, double blind, placebo controlled, multiple ascending dose sequential group study evaluating the safety, tolerability, PK, and PD of once daily SC doses of CB4211 over 7 days in healthy non obese subjects.
Part C: Part C is a randomized, double blind, placebo controlled, multiple dose, parallel group study evaluating the safety, tolerability, PK, and PD of once daily SC doses of CB4211 over 28 days in subjects with NAFLD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Nonalcoholic Fatty Liver Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
This is a 3-part, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, PK, and PD of single- and multiple-ascending SC doses of CB4211 in healthy subjects and subjects with NAFLD. Study treatment (CB4211 or placebo) will be administered SC into the abdomen (and if needed, upper and lower thigh) as bolus injections.
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
randomized, double blind, placebo controlled
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A1 single ascending dose (SAD)
CB4211 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
Group Type
EXPERIMENTAL
CB4211 Dose 1
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Group A2 SAD
CB4211 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
Group Type
EXPERIMENTAL
CB4211 Dose 2
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Group A3 SAD
CB4211 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
Group Type
EXPERIMENTAL
CB4211 Dose 3
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Group A4 SAD
CB4211 Dose 4 (N=1) Placebo (N=1) Subcutaneous injection
Group Type
EXPERIMENTAL
CB4211 Dose 4
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Group A5 SAD
CB4211 Dose 5 (N=6) Placebo (N=2) Subcutaneous injection
Group Type
EXPERIMENTAL
CB4211 Dose 5
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Group A6 SAD
CB4211 Dose 6 (N=6) Placebo (N=2) Subcutaneous injection
Group Type
EXPERIMENTAL
CB4211 Dose 6
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Group B1 multiple ascending dose (MAD)
CB4211 Dose to be determined (TBD) (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
Group Type
EXPERIMENTAL
CB4211 Dose TBD
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Group B2 MAD
CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
Group Type
EXPERIMENTAL
CB4211 Dose TBD
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Group B3 MAD
CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
Group Type
EXPERIMENTAL
CB4211 Dose TBD
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Part C
CB4211 Dose TBD (N=10) Placebo (N=10) Subcutaneous injection once daily for 28 days
Group Type
EXPERIMENTAL
CB4211 Dose TBD
Intervention Type
DRUG
Administered by subcutaneous injection
Placebo
Intervention Type
DRUG
Administered by subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CB4211 Dose 1
Administered by subcutaneous injection
Intervention Type
DRUG
CB4211 Dose 2
Administered by subcutaneous injection
Intervention Type
DRUG
CB4211 Dose 3
Administered by subcutaneous injection
Intervention Type
DRUG
CB4211 Dose 4
Administered by subcutaneous injection
Intervention Type
DRUG
CB4211 Dose 5
Administered by subcutaneous injection
Intervention Type
DRUG
CB4211 Dose 6
Administered by subcutaneous injection
Intervention Type
DRUG
CB4211 Dose TBD
Administered by subcutaneous injection
Intervention Type
DRUG
Placebo
Administered by subcutaneous injection
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Males or females of nonchildbearing potential, of any race, 18 to 60 years of age, inclusive, at Screening.
Females of nonchildbearing potential are defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) confirmed by history or postmenopausal (defined as at least 12 continuous months without menses and follicle-stimulating hormone (FSH) ≥40 milli-International unit (mIU)/L and without an alternative medical cause).
2. Body mass index between 18.0 and 30.0 kg/m2 , inclusive, with a minimum body weight of 50.0 kg at Screening.
3. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[eg, Gilbert's syndrome\] is not acceptable) at Screening or Check-in as assessed by the Investigator (or designee).
4. Males will agree to use contraception.
5. Has maintained stable weight (by history) for at least 4 weeks prior to Screening.
6. Agrees to the following:
* Not to initiate a weight-loss program from Screening until the Follow-up visit;
* To refrain from strenuous exercise from 7 days before Check-in until the Follow-up visit;
* To maintain consistent dietary habits and exercise routines for the duration of the study.
7. Must have transaminases (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)) and total bilirubin within the normal range at Screening and Check-in. For other laboratory evaluations, the subject may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant.
8. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions.
1. Males or females of nonchildbearing potential, of any race, 18 to 60 years of age, inclusive, at Screening.
Females of nonchildbearing potential are defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) confirmed by history or postmenopausal (defined as at least 12 continuous months without menses and FSH ≥40 mIU/L and without an alternative medical cause).
2. Body mass index ≥30.0 kg/m2, and body weight ≤115 kg at Screening.
3. History of Fatty Liver Index (FLI) score \>60, FLI score \>60 at Screening, or documented history of fatty liver with imaging results (eg, standard positive ultrasound or Fibroscan controlled attenuation parameter (CAP) \>300 decibels (dB)/m) indicating liver fat \>10% within 6 months of Screening. A formal diagnosis of nonalcoholic fatty liver disease (NAFLD) is not required.
4. Liver fat content ≥10% as determined by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) within 14 days prior to Check in. One repeat Baseline MRI-PDFF will be allowed if the first value is below 10%, but greater than or equal to 9.5%. The repeat MRI must be within 14 days of the first MRI, and enrollment must be within 14 days of the repeat MRI. The most current MRI will serve as the baseline. (When available, Fibroscan indicating a CAP \>300 dB/m within 6 weeks prior to Check-in may be used as a pre-selection test prior to MRI being performed)
5. No history of common causes of secondary hepatic steatosis such as:
1. Macrovesicular steatosis: excessive alcohol consumption, hepatitis C (genotype 3), Wilson's disease, lipodystrophy, starvation, parenteral nutrition, abetalipoproteinemia, medications (eg, amiodarone, methotrexate, tamoxifen, corticosteroids, or any drug known to affect hepatic steatosis or insulin resistance)
2. Microvesicular steatosis: Reye's syndrome, medications (valproate, anti-retroviral medicines), acute fatty liver of pregnancy, HELLP syndrome, inborn errors of metabolism (eg, lecithin-cholesterol acyltransferase deficiency, cholesterol ester storage disease, Wolman disease, lysosomal acid lipase deficiency)
6. Glycosylated hemoglobin A1c \<7.0 % at Screening.
7. Fasting blood glucose of ≥100 to \<126 mg/dL at Screening.
8. Serum triglyceride level ≤500 mg/dL at Screening
9. Have international normalized ratio (INR) \< upper limit of normal (ULN) and platelet count \>150,000 at Screening and Check-in. For other abnormalities, the subject may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant.
10. In subjects with ALT, AST, alkaline phosphatase (ALP), or total bilirubin \> ULN at Screening, the baseline measurement (BLM) should be determined by 2 separate measurements obtained approximately 4 weeks apart. To be eligible for study entry, the Screening ALT, AST, ALP, and total bilirubin must be \< ULN or the following criteria must be met prior to randomization:
1. ALT ≤3 x ULN for both measurements and the difference between the measurements should be \<20% of the lower value;
2. AST ≤3 x ULN for both measurements and the difference between the measurements should be \<20% of the lowest value;
3. ALP ≤3 x ULN for both measurements and the difference between the measurements should be \<20% of the lowest value;
4. Total bilirubin ≤2 x ULN for both measurements and the difference between the measurements should be \<20% of the lowest value.
11. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[eg, Gilbert's syndrome\] is not acceptable) at Screening or Check-in as assessed by the Investigator (or designee).
12. Males must agree to use contraception.
13. Has maintained stable weight (by history) for at least 4 weeks prior to Screening.
14. Agrees to maintain consistent dietary habits and exercise routines for the duration of the study, including avoiding :
* initiating any weight-loss program from Screening until the Follow-up visit;
* strenuous exercise from 7 days before Check-in until the Follow-up visit;
15. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
Females of nonchildbearing potential are defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) confirmed by history or postmenopausal (defined as at least 12 continuous months without menses and follicle-stimulating hormone (FSH) ≥40 milli-International unit (mIU)/L and without an alternative medical cause).
2. Body mass index between 18.0 and 30.0 kg/m2 , inclusive, with a minimum body weight of 50.0 kg at Screening.
3. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[eg, Gilbert's syndrome\] is not acceptable) at Screening or Check-in as assessed by the Investigator (or designee).
4. Males will agree to use contraception.
5. Has maintained stable weight (by history) for at least 4 weeks prior to Screening.
6. Agrees to the following:
* Not to initiate a weight-loss program from Screening until the Follow-up visit;
* To refrain from strenuous exercise from 7 days before Check-in until the Follow-up visit;
* To maintain consistent dietary habits and exercise routines for the duration of the study.
7. Must have transaminases (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)) and total bilirubin within the normal range at Screening and Check-in. For other laboratory evaluations, the subject may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant.
8. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions.
1. Males or females of nonchildbearing potential, of any race, 18 to 60 years of age, inclusive, at Screening.
Females of nonchildbearing potential are defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) confirmed by history or postmenopausal (defined as at least 12 continuous months without menses and FSH ≥40 mIU/L and without an alternative medical cause).
2. Body mass index ≥30.0 kg/m2, and body weight ≤115 kg at Screening.
3. History of Fatty Liver Index (FLI) score \>60, FLI score \>60 at Screening, or documented history of fatty liver with imaging results (eg, standard positive ultrasound or Fibroscan controlled attenuation parameter (CAP) \>300 decibels (dB)/m) indicating liver fat \>10% within 6 months of Screening. A formal diagnosis of nonalcoholic fatty liver disease (NAFLD) is not required.
4. Liver fat content ≥10% as determined by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) within 14 days prior to Check in. One repeat Baseline MRI-PDFF will be allowed if the first value is below 10%, but greater than or equal to 9.5%. The repeat MRI must be within 14 days of the first MRI, and enrollment must be within 14 days of the repeat MRI. The most current MRI will serve as the baseline. (When available, Fibroscan indicating a CAP \>300 dB/m within 6 weeks prior to Check-in may be used as a pre-selection test prior to MRI being performed)
5. No history of common causes of secondary hepatic steatosis such as:
1. Macrovesicular steatosis: excessive alcohol consumption, hepatitis C (genotype 3), Wilson's disease, lipodystrophy, starvation, parenteral nutrition, abetalipoproteinemia, medications (eg, amiodarone, methotrexate, tamoxifen, corticosteroids, or any drug known to affect hepatic steatosis or insulin resistance)
2. Microvesicular steatosis: Reye's syndrome, medications (valproate, anti-retroviral medicines), acute fatty liver of pregnancy, HELLP syndrome, inborn errors of metabolism (eg, lecithin-cholesterol acyltransferase deficiency, cholesterol ester storage disease, Wolman disease, lysosomal acid lipase deficiency)
6. Glycosylated hemoglobin A1c \<7.0 % at Screening.
7. Fasting blood glucose of ≥100 to \<126 mg/dL at Screening.
8. Serum triglyceride level ≤500 mg/dL at Screening
9. Have international normalized ratio (INR) \< upper limit of normal (ULN) and platelet count \>150,000 at Screening and Check-in. For other abnormalities, the subject may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant.
10. In subjects with ALT, AST, alkaline phosphatase (ALP), or total bilirubin \> ULN at Screening, the baseline measurement (BLM) should be determined by 2 separate measurements obtained approximately 4 weeks apart. To be eligible for study entry, the Screening ALT, AST, ALP, and total bilirubin must be \< ULN or the following criteria must be met prior to randomization:
1. ALT ≤3 x ULN for both measurements and the difference between the measurements should be \<20% of the lower value;
2. AST ≤3 x ULN for both measurements and the difference between the measurements should be \<20% of the lowest value;
3. ALP ≤3 x ULN for both measurements and the difference between the measurements should be \<20% of the lowest value;
4. Total bilirubin ≤2 x ULN for both measurements and the difference between the measurements should be \<20% of the lowest value.
11. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[eg, Gilbert's syndrome\] is not acceptable) at Screening or Check-in as assessed by the Investigator (or designee).
12. Males must agree to use contraception.
13. Has maintained stable weight (by history) for at least 4 weeks prior to Screening.
14. Agrees to maintain consistent dietary habits and exercise routines for the duration of the study, including avoiding :
* initiating any weight-loss program from Screening until the Follow-up visit;
* strenuous exercise from 7 days before Check-in until the Follow-up visit;
15. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
Exclusion Criteria
1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
2. Clinically significant ECG abnormalities or QT interval corrected for heart rate using Fridericia's method (QTcF) \>450 milliseconds for males and \>470 milliseconds for females at either Screening or Check-in, or any prior history of QT abnormality.
3. Creatinine clearance of \<90 mL/min at Screening, determined using the Cockcroft-Gault (C-G) equation.
4. History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
5. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
6. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
7. Alcohol consumption of \>21 units per week for males and \>14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
8. Positive urine drug screen (confirmed by repeat) at Screening or positive alcohol breath or urine test result or positive urine drug screen at Check-in.
9. Positive hepatitis panel and/or positive human immunodeficiency virus test. Subjects with serologic finding of immunity consistent with history of prior hepatitis B vaccination may be enrolled.
10. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing or have received a biological product within 3 months or 5 elimination half-lives (whichever is longer) prior to dosing.
11. Use of prescription drugs, nonprescription drugs, dietary supplements including Vitamin E, herbal supplements, hormonal therapy/replacement, or CYP3A4 substrates, inducers and inhibitors within 14 days prior to the first dose of study drug unless, in the opinion of the Investigator and Sponsor's Medical Monitor, the medication will not interfere with the study procedures or compromise subject safety.
12. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
13. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to the first dose of study medication, unless deemed acceptable by the Investigator (or designee).
14. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in.
15. Receipt of blood products within 2 months prior to Check-in.
16. Donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.
17. Poor peripheral venous access.
18. Have previously completed or withdrawn from this study or any other study investigating CB4211, and have previously received the investigational product.
19. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
1. Significant history or clinical manifestation of any metabolic/endocrine (except for type 2 diabetes), allergic, dermatological, hepatic (except for NAFLD), renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, or psychiatric disorder, as determined by the Investigator (or designee).
2. Clinically significant ECG abnormalities or QTcF \>450 milliseconds for males and 470 milliseconds for females at Screening, or any prior history of QT abnormality.
3. Currently using any antidiabetic medication (eg, insulin, glucagon-like peptide-1 analogs, agonist therapy) other than a stable regimen of metformin (ie, a fixed dose of metformin for \>8 weeks at Screening).
4. Use of fibrates or statins within 6 weeks or beta blocker drugs within 2 weeks prior to Check-in and throughout the duration of the study.
5. Use of Vitamin E, agents associated with changes in liver fat, or agents used for treatment of NAFLD or nonalcoholic steatohepatitis (NASH) within 3 months prior to Screening and throughout the duration of the study.
6. Change in body weight \>5% within the 3 months prior to Check-in.
7. History of bariatric surgery and any other gastrointestinal surgery relative to weight loss (eg, Roux-en-Y gastric bypass, laparoscopic adjustable gastric banding, sleeve gastrectomy, duodenal switch with biliopancreatic diversion).
8. Claustrophobia or other contraindication to magnetic resonance imaging.
9. Creatinine clearance of \<90 mL/min at Screening, determined using the C-G equation.
10. History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
11. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
12. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
13. Alcohol consumption of \>14 units per week for males and \>7 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
14. Positive urine drug screen (confirmed by repeat) at Screening or positive alcohol breath or urine test result or positive urine drug screen at Check-in.
15. Positive hepatitis panel and/or positive human immunodeficiency virus test. Subjects with serologic finding of immunity consistent with history of prior hepatitis B vaccination may be enrolled.
16. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing or have received a biological product within 3 months or 5 elimination half-lives (whichever is longer) prior to dosing.
17. Use of prescription drugs, nonprescription drugs, dietary supplements including peroxisome proliferator-activated receptor-γ agonists, drugs known to affect insulin sensitivity, herbal supplements, hormonal therapy/replacement, or CYP3A4 substrates, inducers, and inhibitors within 14 days or 5 elimination half-lives (whichever is longer) prior to the first dose of study drug and throughout the duration of the study unless, in the opinion of the Investigator and Sponsor's Medical Monitor, the medication will not interfere with the study procedures or compromise subject safety.
18. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
19. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to the first dose of study medication and throughout the duration of the study, unless deemed acceptable by the Investigator (or designee).
20. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in and throughout the duration of the study.
21. Receipt of blood products within 2 months prior to Check-in and throughout the duration of the study.
22. Donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.
23. Poor peripheral venous access.
24. Have previously completed or withdrawn from this study or any other study investigating CB4211, and have previously received the investigational product.
25. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
2. Clinically significant ECG abnormalities or QT interval corrected for heart rate using Fridericia's method (QTcF) \>450 milliseconds for males and \>470 milliseconds for females at either Screening or Check-in, or any prior history of QT abnormality.
3. Creatinine clearance of \<90 mL/min at Screening, determined using the Cockcroft-Gault (C-G) equation.
4. History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
5. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
6. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
7. Alcohol consumption of \>21 units per week for males and \>14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
8. Positive urine drug screen (confirmed by repeat) at Screening or positive alcohol breath or urine test result or positive urine drug screen at Check-in.
9. Positive hepatitis panel and/or positive human immunodeficiency virus test. Subjects with serologic finding of immunity consistent with history of prior hepatitis B vaccination may be enrolled.
10. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing or have received a biological product within 3 months or 5 elimination half-lives (whichever is longer) prior to dosing.
11. Use of prescription drugs, nonprescription drugs, dietary supplements including Vitamin E, herbal supplements, hormonal therapy/replacement, or CYP3A4 substrates, inducers and inhibitors within 14 days prior to the first dose of study drug unless, in the opinion of the Investigator and Sponsor's Medical Monitor, the medication will not interfere with the study procedures or compromise subject safety.
12. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
13. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to the first dose of study medication, unless deemed acceptable by the Investigator (or designee).
14. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in.
15. Receipt of blood products within 2 months prior to Check-in.
16. Donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.
17. Poor peripheral venous access.
18. Have previously completed or withdrawn from this study or any other study investigating CB4211, and have previously received the investigational product.
19. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
1. Significant history or clinical manifestation of any metabolic/endocrine (except for type 2 diabetes), allergic, dermatological, hepatic (except for NAFLD), renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, or psychiatric disorder, as determined by the Investigator (or designee).
2. Clinically significant ECG abnormalities or QTcF \>450 milliseconds for males and 470 milliseconds for females at Screening, or any prior history of QT abnormality.
3. Currently using any antidiabetic medication (eg, insulin, glucagon-like peptide-1 analogs, agonist therapy) other than a stable regimen of metformin (ie, a fixed dose of metformin for \>8 weeks at Screening).
4. Use of fibrates or statins within 6 weeks or beta blocker drugs within 2 weeks prior to Check-in and throughout the duration of the study.
5. Use of Vitamin E, agents associated with changes in liver fat, or agents used for treatment of NAFLD or nonalcoholic steatohepatitis (NASH) within 3 months prior to Screening and throughout the duration of the study.
6. Change in body weight \>5% within the 3 months prior to Check-in.
7. History of bariatric surgery and any other gastrointestinal surgery relative to weight loss (eg, Roux-en-Y gastric bypass, laparoscopic adjustable gastric banding, sleeve gastrectomy, duodenal switch with biliopancreatic diversion).
8. Claustrophobia or other contraindication to magnetic resonance imaging.
9. Creatinine clearance of \<90 mL/min at Screening, determined using the C-G equation.
10. History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
11. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
12. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
13. Alcohol consumption of \>14 units per week for males and \>7 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
14. Positive urine drug screen (confirmed by repeat) at Screening or positive alcohol breath or urine test result or positive urine drug screen at Check-in.
15. Positive hepatitis panel and/or positive human immunodeficiency virus test. Subjects with serologic finding of immunity consistent with history of prior hepatitis B vaccination may be enrolled.
16. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing or have received a biological product within 3 months or 5 elimination half-lives (whichever is longer) prior to dosing.
17. Use of prescription drugs, nonprescription drugs, dietary supplements including peroxisome proliferator-activated receptor-γ agonists, drugs known to affect insulin sensitivity, herbal supplements, hormonal therapy/replacement, or CYP3A4 substrates, inducers, and inhibitors within 14 days or 5 elimination half-lives (whichever is longer) prior to the first dose of study drug and throughout the duration of the study unless, in the opinion of the Investigator and Sponsor's Medical Monitor, the medication will not interfere with the study procedures or compromise subject safety.
18. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
19. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to the first dose of study medication and throughout the duration of the study, unless deemed acceptable by the Investigator (or designee).
20. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in and throughout the duration of the study.
21. Receipt of blood products within 2 months prior to Check-in and throughout the duration of the study.
22. Donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.
23. Poor peripheral venous access.
24. Have previously completed or withdrawn from this study or any other study investigating CB4211, and have previously received the investigational product.
25. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CohBar, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ProScietno
Chula Vista, California, United States
Site Status
Covance Clinical Research Unit Inc.
Dallas, Texas, United States
Site Status
The Texas Liver Institute
San Antonio, Texas, United States
Site Status
Endeavor Clinical Trials, LLC
San Antonio, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Jiang J, Xu L, Yang L, Liu S, Wang Z. Mitochondrial-Derived Peptide MOTS-c Ameliorates Spared Nerve Injury-Induced Neuropathic Pain in Mice by Inhibiting Microglia Activation and Neuronal Oxidative Damage in the Spinal Cord via the AMPK Pathway. ACS Chem Neurosci. 2023 Jun 21;14(12):2362-2374. doi: 10.1021/acschemneuro.3c00140. Epub 2023 Jun 7.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CB-4211-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
NCT05462353
ACTIVE_NOT_RECRUITING
PHASE2
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
NCT06054815
COMPLETED
PHASE2
A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
NCT04844450
COMPLETED
PHASE1
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
NCT05364931
COMPLETED
PHASE2
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
NCT04048135
COMPLETED
PHASE1/PHASE2
Study in Healthy Adults Evaluating PF-07202954
NCT04857437
COMPLETED
PHASE1
Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
NCT04857606
COMPLETED
PHASE1
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
NCT07128797
RECRUITING
PHASE1
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
NCT07214870
RECRUITING
PHASE1
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03248882
COMPLETED
PHASE2
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
NCT03776175
COMPLETED
PHASE2
A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
NCT05917938
COMPLETED
PHASE1
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
NCT05006885
COMPLETED
PHASE1
Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
NCT00706537
COMPLETED
PHASE1
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
NCT02854605
COMPLETED
PHASE2
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
NCT03439254
COMPLETED
PHASE3
A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease
NCT01277094
COMPLETED
PHASE1
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
NCT02442687
COMPLETED
PHASE2
A Phase 2b Study of Icosabutate in Fatty Liver Disease
NCT04052516
COMPLETED
PHASE2
The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis
NCT04134091
COMPLETED
PHASE2
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
NCT05118360
WITHDRAWN
PHASE2
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
NCT04483947
COMPLETED
PHASE1
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
NCT05809934
COMPLETED
PHASE2
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
NCT02316717
COMPLETED
PHASE2
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
NCT04505436
ACTIVE_NOT_RECRUITING
PHASE2